https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
Modulation of Gut Microbiota by Rifaximin in PD Patients
DESCRIPTION:
Conditions: Parkinson Disease; Inflammation
Intervention: Drug: Rifaximin 550 MG
Sponsor: Taipei Medical University Shuang Ho Hospital
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03958708
FIRST POSTED:
Wed, 22 May 2019 12:00:00 EDT
LAST UPDATE POSTED:
05/22/19 07:42AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst